NO20032027L - Effektive antitumorbehandlinger - Google Patents

Effektive antitumorbehandlinger

Info

Publication number
NO20032027L
NO20032027L NO20032027A NO20032027A NO20032027L NO 20032027 L NO20032027 L NO 20032027L NO 20032027 A NO20032027 A NO 20032027A NO 20032027 A NO20032027 A NO 20032027A NO 20032027 L NO20032027 L NO 20032027L
Authority
NO
Norway
Prior art keywords
effective anti
tumor treatments
tumor
treatments
tumour
Prior art date
Application number
NO20032027A
Other languages
English (en)
Other versions
NO329981B1 (no
NO20032027D0 (no
Inventor
Naoto Takahashi
Steve Weitman
Incalci Maurizio D
Glynn Thomas Faicloth
Rafaella Giavazzi
Andreas Gescher
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27399908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20032027(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of NO20032027D0 publication Critical patent/NO20032027D0/no
Publication of NO20032027L publication Critical patent/NO20032027L/no
Publication of NO329981B1 publication Critical patent/NO329981B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20032027A 2000-11-06 2003-05-06 Anvendelse av ET-743 ved fremstilling av et medikament, samt synergistisk kombinasjon som omfatter ET-743 og et annet antitumorlegemiddel. NO329981B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24623300P 2000-11-06 2000-11-06
US24809500P 2000-11-13 2000-11-13
US34598201P 2001-10-19 2001-10-19
PCT/GB2001/004902 WO2002036135A2 (en) 2000-11-06 2001-11-06 Compositions for antitumour treatment containing ecteinascidin 743

Publications (3)

Publication Number Publication Date
NO20032027D0 NO20032027D0 (no) 2003-05-06
NO20032027L true NO20032027L (no) 2003-07-04
NO329981B1 NO329981B1 (no) 2011-01-31

Family

ID=27399908

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032027A NO329981B1 (no) 2000-11-06 2003-05-06 Anvendelse av ET-743 ved fremstilling av et medikament, samt synergistisk kombinasjon som omfatter ET-743 og et annet antitumorlegemiddel.

Country Status (24)

Country Link
US (3) US20040108086A1 (no)
EP (1) EP1365808B1 (no)
JP (2) JP4391083B2 (no)
KR (1) KR100718946B1 (no)
CN (1) CN100374162C (no)
AT (1) ATE495793T1 (no)
AU (2) AU2002212499B2 (no)
BG (1) BG107843A (no)
BR (1) BR0115162A (no)
CA (1) CA2428160C (no)
CY (1) CY1112361T1 (no)
CZ (1) CZ20031327A3 (no)
DE (1) DE60143911D1 (no)
DK (1) DK1365808T3 (no)
EA (1) EA005564B1 (no)
HU (1) HUP0400648A3 (no)
IL (1) IL155781A0 (no)
MX (1) MXPA03003975A (no)
NO (1) NO329981B1 (no)
NZ (1) NZ525730A (no)
PL (1) PL361389A1 (no)
PT (1) PT1365808E (no)
SK (1) SK287901B6 (no)
WO (1) WO2002036135A2 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
WO2002036135A2 (en) * 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
PL368458A1 (en) * 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
JP2007511499A (ja) 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
JP2007511509A (ja) * 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
JP2008505862A (ja) * 2004-07-09 2008-02-28 ファルマ、マール、ソシエダード、アノニマ 予後分子マーカー
WO2006035244A2 (en) * 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
RS50822B (sr) * 2004-10-26 2010-08-31 Pharma Mar S.A., Sociedad Unipersonal Pegilovani lipozomalni doksorubicin u kombinaciji sa ekteinescidinom 743
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
JP2009517403A (ja) * 2005-11-25 2009-04-30 ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュージャージー Ｐａｒｐ−１阻害剤の使用
WO2009050303A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for et-743 treatment
EP2786755A3 (en) * 2010-11-12 2014-10-29 Pharma Mar S.A. Combination therapy with an antitumor alkaloid
GB201217439D0 (en) * 2012-09-28 2012-11-14 Topotarget As Combination therapy
WO2014165818A2 (en) 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions and methods for preventing and treating prostate cancer
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
CN109276719A (zh) * 2018-11-01 2019-01-29 中山万汉制药有限公司 含有奥利司他纳米粒与蛋白激酶抑制剂的组合物
CA3158733A1 (en) 2019-11-21 2021-05-27 Pilar Calvo Methods of treating small cell lung cancer with lurbinectedin formulations
EP3960177A1 (en) * 2020-08-26 2022-03-02 Anturec Pharmaceuticals GmbH Composition comprising ttf-ngr for use in treating soft-tissue sarcoma

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
WO1998052598A1 (en) * 1997-05-21 1998-11-26 Genentech, Inc. Novel administration of thrombopoietin
BR9909488B1 (pt) * 1998-04-06 2011-02-08 ecteinascidinas semi-sintéticas e composição farmacêutica.
IL139607A0 (en) * 1998-05-11 2002-02-10 Pharma Mar Sa Metabolites of ecteinascidin 743
JP2000081438A (ja) * 1998-06-25 2000-03-21 Sekisui Chem Co Ltd 被験者の癌化学療法による免疫機能低下の測定方法
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US20020137663A1 (en) * 2000-08-11 2002-09-26 Forman Barry M. The anti-neoplastic agent ET-743 inhibits trans activation by SXR
WO2002036135A2 (en) * 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
US6770653B2 (en) * 2001-03-06 2004-08-03 Bristol-Myers Squibb Company Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
JP4391038B2 (ja) * 2001-05-10 2009-12-24 パナソニック株式会社 電気炊飯器
PL368458A1 (en) * 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
JP2007511499A (ja) * 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
JP2007511509A (ja) * 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
JP2008505862A (ja) * 2004-07-09 2008-02-28 ファルマ、マール、ソシエダード、アノニマ 予後分子マーカー
WO2006035244A2 (en) * 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
RS50822B (sr) * 2004-10-26 2010-08-31 Pharma Mar S.A., Sociedad Unipersonal Pegilovani lipozomalni doksorubicin u kombinaciji sa ekteinescidinom 743
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
JP2009517403A (ja) * 2005-11-25 2009-04-30 ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュージャージー Ｐａｒｐ−１阻害剤の使用
WO2007134203A2 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin

Also Published As

Publication number Publication date
CZ20031327A3 (cs) 2003-11-12
CY1112361T1 (el) 2015-12-09
WO2002036135A3 (en) 2003-04-10
JP2009114212A (ja) 2009-05-28
NZ525730A (en) 2004-12-24
NO329981B1 (no) 2011-01-31
AU1249902A (en) 2002-05-15
KR20030048127A (ko) 2003-06-18
AU2002212499B2 (en) 2006-11-02
CN1486193A (zh) 2004-03-31
SK287901B6 (sk) 2012-03-02
MXPA03003975A (es) 2004-02-12
DE60143911D1 (de) 2011-03-03
EA200300544A1 (ru) 2003-08-28
BG107843A (bg) 2004-06-30
KR100718946B1 (ko) 2007-05-16
CA2428160C (en) 2009-10-13
US20040108086A1 (en) 2004-06-10
PT1365808E (pt) 2011-04-08
JP4391083B2 (ja) 2009-12-24
DK1365808T3 (da) 2011-05-16
WO2002036135A2 (en) 2002-05-10
CN100374162C (zh) 2008-03-12
SK5492003A3 (en) 2004-03-02
PL361389A1 (en) 2004-10-04
US20090324744A1 (en) 2009-12-31
EP1365808B1 (en) 2011-01-19
JP2004517056A (ja) 2004-06-10
NO20032027D0 (no) 2003-05-06
HUP0400648A2 (hu) 2004-06-28
EA005564B1 (ru) 2005-04-28
CA2428160A1 (en) 2002-05-10
BR0115162A (pt) 2003-10-21
EP1365808A2 (en) 2003-12-03
HK1060067A1 (en) 2004-07-30
HUP0400648A3 (en) 2012-09-28
ATE495793T1 (de) 2011-02-15
US20120107417A1 (en) 2012-05-03
IL155781A0 (en) 2003-12-23

Similar Documents

Publication Publication Date Title
NO20032027D0 (no) Effektive antitumorbehandlinger
CY1112753T1 (el) Θεραπευτικη αγωγη καρκινων του ανθρωπινου σωματος με τη χρηση toy ετ743
NZ544472A (en) Compounds and therapeutical use thereof
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
DK1223980T3 (da) Anvendelse af CSF-1-inhibitorer
DK1565471T3 (da) Quionolinylpyrazoler
TR200002786T2 (tr) Meloksikam için yeni galenik bir formülasyon.
CY1109229T1 (el) Χρηση σπογγοσινης (2-μεθοξυαδενοσινης) για τη θεραπεια πονου, συγκεκριμενα υπερευαισθησιας στο πονο
CY1108629T1 (el) Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου
UY27812A1 (es) Uso de docetasel-doxorubin-ciclofosfamida como apoyo de terapias
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
PT1030667E (pt) Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono
FI20020197A0 (fi) Yhdistelmä akuutin myokardiilisen infarktin hoitoon
EA200300427A1 (ru) Противоопухолевая терапия, включающая производные дистамицина
GEP201606538B (en) Preoperative treatment of post operative pain
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
EE200200549A (et) Jagatud doosi teraapia veresooni kahjustava aktiivsusega
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
DK1150981T3 (da) Terapeutisk necleosidforbindelse
NO20043774L (no) The use of devazenide as analgesic agent
UA40393A (uk) Спосіб лікування хронічного обструктивного бронхіту
UA44635A (uk) Спосіб імунотерапії раку молочної залози

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees